Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRMakoto Maemondo, Toshihiro Nukiwa, Akira Inoue et al.|New England Journal of Medicine|2010Cited by 5.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Makoto Maemondo, Satoshi Watanabe et al.|The Lancet Oncology|2019Cited by 636
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for ChemotherapyAkira Inoue, Koichi Hagiwara, Kunihiko Kobayashi et al.|Journal of Clinical Oncology|2009Cited by 516
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 StudyYukio Hosomi, Satoshi Morita, Shunichi Sugawara et al.|Journal of Clinical Oncology|2019Cited by 483
MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting <i>MAGI2</i> in Lung Adenocarcinoma CellsKazuhiro Kitamura, Akihiko Gemma|Molecular Cancer Therapeutics|2013Cited by 186